Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib-Reference-Cited by-同舟云学术

Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib

Published:2024-01-11 Issue:2 Volume:143 Page:178-182
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Rampotas Alex¹,Carter-Brzezinski Luke²³,Somervaille Tim C. P.²³,Forryan James¹,Panitsas Fotios⁴^ORCID,Harrison Claire⁵,Witherall Ruth⁶,Innes Andrew J.⁷^ORCID,Wallis Louise⁸,Butt Naumann M.⁹,Psaila Bethan¹⁰^ORCID,Mead Adam J.¹⁰^ORCID,Carter Matthew¹¹,Godfrey Anna L.¹¹,Laing Heather¹²,Garg Mamta¹²^ORCID,Francis Sebastian¹³,Ewing Joanne¹⁴,Teh Chun Huat¹⁵,Cowen Hannah Bibi⁵,Dyer Peter¹⁶,McConville Conall¹⁷,Wadelin Frances¹⁸,Sahra Ali¹⁹,McGregor Andrew²⁰,Kulakov Elizabeth²¹,McLornan Donal P.¹,Lambert Jonathan¹

Affiliation:

1. 1Haematology Department, University College London Hospital NHS Foundation Trust, London, United Kingdom

2. 2Cancer Research UK Manchester Institute, Manchester, United Kingdom

3. 3Haematology Department, The Christie NHS Foundation Trust, Manchester, United Kingdom

4. 4Haematology Department, Laikon University Hospital of Athens, Athens, Greece

5. 5Haematology Department, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

6. 6Haematology Department, Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom

7. 7Haematology Department, Imperial College Healthcare NHS Trust, London, United Kingdom

8. 8Haematology Department, University Hospitals Dorset NHS Foundation Trust, Bournemouth, United Kingdom

9. 9Haematology Department, The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom

10. 10Department of Haematology and NIHR Biomedical Research Centre, OUH NHS Foundation Trust, Oxford, United Kingdom

11. 11Haematology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

12. 12University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

13. 13Haematology Department, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom

14. 14Haematology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

15. 15Haematology Department, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

16. 16Haematology Department, University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom

17. 17Department of Haematology, Altnagelvin Area Hospital, North West Cancer Centre, Derry, United Kingdom

18. 18Haematology Department, Nottingham University Hospital NHS Foundation Trust, Nottingham, United Kingdom

19. 19Haematology Department, King’s College London Hospital NHS Foundation Trust, London, United Kingdom

20. 20Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom

21. 21Dermatology Department, University College London Hospital NHS Foundation Trust, London, United Kingdom

Abstract

Abstract Nonmelanoma skin cancers (NMSCs) in ruxolitinib-treated patients with myeloproliferative neoplasms behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis. Vigilant skin assessment, counseling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

https://ashpublications.org/blood/article-pdf/143/2/178/2180218/blood_bld-2023-022345-main.pdf

Reference14 articles.

1. Skin cancers under Janus kinase inhibitors: a World Health Organization drug safety database analysis;Jalles;Therapie,2022

2. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis;Lin;J Am Acad Dermatol,2022

3. Aggressive skin cancers occurring in patients treated with the janus kinase inhibitor ruxolitinib;Blechman;J Drugs Dermatol,2017

4. Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients;Maffioli;Blood Adv,2019

5. Jakavi 10mg tablets: summary of product characteristics (SmPC). electronic medicines compendium (emc). Accessed 31 July 2023. https://www.medicines.org.uk/emc/product/7786/smpc.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JAK inhibitor selectivity: new opportunities, better drugs?;Nature Reviews Rheumatology;2024-09-09

2. A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis;Annals of Hematology;2024-08-15

3. Increased Risk of Keratinocyte Carcinomas, Merkel Cell Carcinoma, and Other Skin Cancers in Patients Treated With Janus Kinase 1 and 2 Inhibitor, Ruxolitinib;Journal of Cutaneous Medicine and Surgery;2024-06-10

4. Treatment‐associated decline in JAK2V617F allele burden in polycythemia vera: What does it mean?;American Journal of Hematology;2024-05-20

5. A safety evaluation of ruxolitinib for the treatment of polycythemia vera;Expert Opinion on Drug Safety;2023-12-29